PeterMGlazerMDPhD

Radiation Oncology • New Haven, CT

Chairman, Department of Therapeutic Radiology, Yale University

Join to view full profile

Dr. Glazer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Glazer's full profile

Already have an account?

Office
15 York St
Hunter Buildign
New Haven, CT 06510
Phone+1 203-688-1861

Fax+1 203-688-1863

Education & Training

Yale-New Haven Medical CenterResidency, Radiation Oncology, 1988 - 1991
Yale School of MedicineClass of 1987

Certifications & Licensure

CT State Medical License 1991 - 2025
American Board of Radiology Radiation Oncology

Publications & Presentations

PubMed

Tumor-specific antigen delivery for T-cell therapy via a pH-sensitive peptide conjugate.
Annali M Yurkevicz, Yanfeng Liu, Samuel G Katz, Peter M Glazer
Molecular Cancer Therapeutics. 2024-10-09
Peptide Nucleic Acid-Mediated Regulation of CRISPR-Cas9 Specificity.
Kelly E W Carufe, Nicholas G Economos, Peter M Glazer
Nucleic Acid Therapeutics. 2024-10-01
1 citations
Next-generation cell-penetrating antibodies for tumor targeting and RAD51 inhibition.
Madison Rackear, Elias Quijano, Zaira Ianniello, Daniel A Colón-Ríos, Adam Krysztofiak
Oncotarget. 2024-10-01

Journal Articles

Krebs-Cycle-Deficient Hereditary Cancer Syndromes Are Defined by Defects in Homologous-Recombination DNA Repair
Brian Shuch, Ranjit S Bindra, Christopher D Corso, Peter M Glazer, Nature
In Utero Nanoparticle Delivery for Site-Specific Genome Editing
Peter M. Glazer, Valerie L. Luks, David H. Stitelman, Eric Song, Nature

Press Mentions

RefleXion Announces Installation of X1 Platform at Smilow Cancer Hospital at Yale New HavenMarch 1st, 2023
Student Research Day Celebrates Students and MentorsJune 1st, 2021
Cybrexa Therapeutics Appoints Vishwas Paralkar, Ph.D. As Chief Scientific OfficerSeptember 20th, 2017
Join now to see all

Grant Support

Novel Triplex-Engineered, Brca1-Mutated Cell Lines For ResearchNational Institute Of Environmental Health Sciences2012
Epigenetic Regulation In Hypoxic Cancer CellsNational Cancer Institute2010–2012
Hypoxia, Genetic Instability And DNA Mismatch RepairNational Institute Of Environmental Health Sciences2003–2012
Research Programs-Radiobiology And RadiotherapyNational Cancer Institute2007–2011
Homology- Dependent DNA Repair, Hypoxia, And Cancer TherapyNational Cancer Institute2007–2011
DNA Repair In Cancer Biology And TherapyNational Cancer Institute2007–2011
Targeted Correction Of The Human Beta-Globin GeneNational Heart, Lung, And Blood Institute2007–2010
Cisplatin Damage Response And Cell-To-Cell CommunicationNational Cancer Institute2005–2009
Research Training: Radiation Therapy, Biology, PhysicsNational Cancer Institute1997–2009
Targeted Mutagenesis Of DNA VIA Triple Helix FormationNational Cancer Institute1995–2008
AdministrativeNational Cancer Institute2007
Recombination Induced By Triple Helix FormationNational Institute Of General Medical Sciences2001–2004
Genetic Instability Induced By Viral ProteinsNational Cancer Institute1999–2002
Mutagenesis In DNA Mismatch Repair Deficient MiceNational Institute Of Environmental Health Sciences1998–2002
Recombination Induced By Triplex Targeted DNA DamageNational Institute Of General Medical Sciences1997–2000
Xray Induced MutagenesisNational Institute Of Environmental Health Sciences1997
Xray Induced Mutagenesis In Transgenic MiceNational Institute Of Environmental Health Sciences1994–1996
X-RAY Induced Mutagenesis In Transgenic MiceNational Institute Of Environmental Health Sciences1992–1993